AbbVie: Bulletproof Fundamentals

vzphotos Investment thesis AbbVie (NYSE:ABBV) is a profitability superstar, generating almost 40% in free cash flow margin even when I deduct stock-based compensation. The company has a stellar revenue growth trajectory over the past decade, which was fueled mostly by strategic acquisitions. The approach is aggressive, but AbbVie's strong track record of success increases my confidence in future growth. AbbVie has a diverse portfolio of products across several promising drug markets. The valuation looks ...